These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

773 related items for PubMed ID: 12802025

  • 21. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
    Campbell B, Wirth A, Milner A, Di Iulio J, MacManus M, Ryan G.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1538-45. PubMed ID: 16125872
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
    Salloum E, Doria R, Farber LR, Roberts KB, Cooper DL.
    Cancer J Sci Am; 1995 Dec 01; 1(4):267-73. PubMed ID: 9166487
    [Abstract] [Full Text] [Related]

  • 24. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
    Klimo P, Connors JM.
    Semin Hematol; 1988 Apr 01; 25(2 Suppl 2):34-40. PubMed ID: 2456621
    [Abstract] [Full Text] [Related]

  • 25. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I, Ganser D, Freitag EM, Bohndorf W.
    Strahlenther Onkol; 1994 Sep 01; 170(9):516-23. PubMed ID: 7524173
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY.
    Ai Zheng; 2006 Aug 01; 25(8):1013-8. PubMed ID: 16965685
    [Abstract] [Full Text] [Related]

  • 28. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M, Ditonno P, Lorusso V, Timurian A, Pellecchia A, Brandi M, Berardi F, Marzullo F.
    Haematologica; 1993 Aug 01; 78(4):230-5. PubMed ID: 7507457
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):860-5. PubMed ID: 15925455
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
    Petera J, Macharová H, Pohanková R, Malír A, Coupek P, Konecný M, Patera J, Pecina J, Drbal J, Koukalová H, Vásová I.
    Neoplasma; 2000 Nov 01; 47(2):129-32. PubMed ID: 10985481
    [Abstract] [Full Text] [Related]

  • 35. [Improved survival rates in Hodgkin's disease].
    Hayabuchi N, Jingu K, Miyoshi M, Hirata H, Masuda K, Shibuya T, Nishimura J, Komiyama S, Ishii E, Kikuchi M.
    Gan No Rinsho; 1988 Apr 01; 34(5):698-704. PubMed ID: 2455073
    [Abstract] [Full Text] [Related]

  • 36. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
    Hudson MM, Krasin M, Link MP, Donaldson SS, Billups C, Merchant TE, Kun L, Billet AL, Kaste S, Tarbell NJ, Howard S, Friedmann AM, Hurwitz CA, Young JA, Marcus KC, Rai S, Cowan T, Weinstein HJ.
    J Clin Oncol; 2004 Nov 15; 22(22):4541-50. PubMed ID: 15542805
    [Abstract] [Full Text] [Related]

  • 37. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B.
    J Clin Oncol; 1997 Apr 15; 15(4):1638-45. PubMed ID: 9193364
    [Abstract] [Full Text] [Related]

  • 38. Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.
    Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F, Campana F, Fourquet A, Bollet MA.
    Int J Radiat Oncol Biol Phys; 2012 Feb 01; 82(2):e145-52. PubMed ID: 21605948
    [Abstract] [Full Text] [Related]

  • 39. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease.
    Aversa SM, Salvagno L, Sorarù M, Mazzarotto R, Boso C, Gaion F, Chiarion-Sileni V, De Franchis G, Favaretto AG, Crivellari G, Banna GL, Sotti G, Monfardini S.
    Acta Haematol; 2004 Feb 01; 112(3):141-7. PubMed ID: 15345896
    [Abstract] [Full Text] [Related]

  • 40. [Our experiences in treating patients with Hodgkin disease in the last decade].
    Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G, Gergely L, Illés A.
    Orv Hetil; 2007 Apr 15; 148(15):675-82. PubMed ID: 17416575
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.